The phase II CodeBreaK100 trial recently showed promising results for the use of sotorasib, a small molecule that irreversibly inhibits KRAS G12C, in pretreated KRAS p.G12C-mutated NSCLC [125]. Here, KRAS is linked to non-small cell lung carcinoma.